Management of refractory ulcerative colitis.

Area of Science:

• Gastroenterology
• Internal Medicine

Background:

• Ulcerative colitis (UC) management presents challenges when patients are refractory to standard therapies.
• Accurate diagnosis and exclusion of other conditions are crucial before initiating advanced treatment.

Purpose of the Study:

• To outline a systematic approach for physicians managing ulcerative colitis patients refractory to first-line treatments.
• To review current and novel medical, dietary, and surgical options for refractory UC.

Main Methods:

• Systematic review of diagnostic considerations, including differential diagnoses and confirming inflammation via flexible sigmoidoscopy.
• Evaluation of established medical therapies such as azathioprine (AZA), 6-mercaptopurine (6-MP), and biologics (infliximab).
• Consideration of alternative and novel therapeutic agents, alongside surgical intervention.

Main Results:

• Accurate diagnosis is paramount, ruling out infections, incorrect diagnoses, or other contributing factors.
• Purine analogues (AZA, 6-MP) are the cornerstone of long-term medical therapy for refractory UC.
• For rapid remission induction, agents like infliximab, cyclosporine, or tacrolimus may be necessary; long-term maintenance is essential to prevent relapse.

Conclusions:

• A comprehensive strategy integrating medical, dietary, and surgical options is vital for refractory UC.
• Long-term maintenance therapy with agents like AZA, 6-MP, or infliximab is critical for sustained remission.
• Novel therapies are emerging, and surgical options should be considered proactively in the treatment plan.